Amgen announces positive Phase 3 Aranesp results
Amgen announced this week that the Phase 3 Aranesp (darbepoetin alfa) ARCADE trial succeeded in reducing the occurrence of red blood cell transfusions for patients with low and intermediate-1 risk Myelodysplastic Syndrome (MDS) who are also anemic. Read More »